Compare OLLI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLLI | TLX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 3.3B |
| IPO Year | 2015 | N/A |
| Metric | OLLI | TLX |
|---|---|---|
| Price | $114.11 | $9.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $140.69 | $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 108.9K |
| Earning Date | 12-09-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.35 | N/A |
| EPS | ★ 3.61 | 0.04 |
| Revenue | ★ $2,537,026,000.00 | $664,225,558.00 |
| Revenue This Year | $18.68 | N/A |
| Revenue Next Year | $12.76 | N/A |
| P/E Ratio | ★ $31.77 | $284.97 |
| Revenue Growth | 12.58 | ★ 55.35 |
| 52 Week Low | $94.88 | $8.76 |
| 52 Week High | $141.74 | $30.36 |
| Indicator | OLLI | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 38.74 |
| Support Level | $109.22 | $9.37 |
| Resistance Level | $118.72 | $10.03 |
| Average True Range (ATR) | 5.15 | 0.25 |
| MACD | -0.72 | -0.00 |
| Stochastic Oscillator | 25.33 | 7.65 |
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name brand household related items that consumers use in their everyday lives at prices that are heavily discounted below traditional retailers. It offers customers a broad selection of brand name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.